Molecular features of non-selective small molecule antagonists of the Bradykinin receptors
Visualitza/Obre
Cita com:
hdl:2117/334784
Tipus de documentArticle
Data publicació2020-09-21
Condicions d'accésAccés obert
Llevat que s'hi indiqui el contrari, els
continguts d'aquesta obra estan subjectes a la llicència de Creative Commons
:
Reconeixement 4.0 Internacional
Abstract
Angiotensin converting enzyme 2 (ACE2) downregulation is a key negative factor for the severity of lung edema and acute lung failure observed in patients infected with SARS-CoV-2. ACE2 downregulation affects the levels of diverse peptide mediators of the renin-agiotensin-aldestosterone and kallikrein-kinin systems, compromising vascular hemostasis. Increasing evidence suggests that the inflammatory response observed in covid-19 patients is initiated by the action of kinins on the bradykinin receptors. Accordingly, the use of bradykinin antagonists should be considered as a strategy for therapeutic intervention against covid-19 illness progression. Presently, icatibant is the only bradykinin antagonist drug approved. In the present report, we investigated the molecular features characterizing non-selective antagonists targeting the bradykinin receptors and carried out a in silico screening of approved drugs, aimed at the identification of compounds with a non-selective bradykinin antagonist profile that can be evaluated for drug repurposing. The study permitted to identify eight compounds as prospective non-selective antagonists of the bradykinin receptors, including raloxifene; sildenafil; cefepime; cefpirome; imatinib; ponatinib; abemaciclib and entrectinib.
CitacióRasaeifar, B.; Gomez-Gutierrez, P.; Perez, J. Molecular features of non-selective small molecule antagonists of the Bradykinin receptors. "Pharmaceuticals", 21 Setembre 2020, vol. 13, núm. 9, p. 259:1-259:10.
ISSN1424-8247
Versió de l'editorhttps://www.mdpi.com/1424-8247/13/9/259
Fitxers | Descripció | Mida | Format | Visualitza |
---|---|---|---|---|
pharmaceuticals-13-00259.pdf | 749,6Kb | Visualitza/Obre |